Aurinia Pharmaceuticals Inc. (AUPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 30M 60M 90M Q3 '21: 14.7M Q4 '21: 23.4M Q1 '22: 21.6M Q2 '22: 28.2M Q3 '22: 55.8M Q4 '22: 28.4M Q1 '23: 34.4M Q2 '23: 41.5M Q3 '23: 54.5M Q4 '23: 45.1M Q1 '24: 50.3M Q2 '24: 57.2M Q3 '24: 67.8M Q4 '24: 59.9M Q1 '25: 62.5M Q2 '25: 70M Q3 '25: 73.5M Q4 '25: 77.1M Q1 '26: 77.7M Q2 '26: 83.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 30M 60M 90M Q3 '21: 14.4M Q4 '21: 22.9M Q1 '22: 21.4M Q2 '22: 26.6M Q3 '22: 53.3M Q4 '22: 27.1M Q1 '23: 34M Q2 '23: 39.9M Q3 '23: 47.7M Q4 '23: 39.7M Q1 '24: 42.6M Q2 '24: 48.3M Q3 '24: 61.7M Q4 '24: 54.3M Q1 '25: 53.9M Q2 '25: 62.9M Q3 '25: 65.3M Q4 '25: 68.3M Q1 '26: 71.2M Q2 '26: 76.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -50.4M Q4 '21: -32.7M Q1 '22: -37.9M Q2 '22: -36M Q3 '22: -9.5M Q4 '22: -28.1M Q1 '23: -29.6M Q2 '23: -16.2M Q3 '23: -16.3M Q4 '23: -29.7M Q1 '24: -13.3M Q2 '24: -1.5M Q3 '24: 11.7M Q4 '24: -1.7M Q1 '25: 21.8M Q2 '25: 20.1M Q3 '25: 29.7M Q4 '25: 33.2M Q1 '26: 41.4M Q2 '26: 46.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-80M 0 80M 160M 240M Q3 '21: -50.3M Q4 '21: -33.3M Q1 '22: -37.6M Q2 '22: -35.5M Q3 '22: -9M Q4 '22: -26M Q1 '23: -26.2M Q2 '23: -11.5M Q3 '23: -13.4M Q4 '23: -26.9M Q1 '24: -10.7M Q2 '24: 722K Q3 '24: 14.3M Q4 '24: 1.4M Q1 '25: 23.3M Q2 '25: 21.5M Q3 '25: 31.6M Q4 '25: 210.8M Q1 '26: 34.4M Q2 '26: 37.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 3.5M 7M 10.5M Q3 '21: 254K Q4 '21: 481K Q1 '22: 256K Q2 '22: 1.6M Q3 '22: 2.4M Q4 '22: 1.4M Q1 '23: 421K Q2 '23: 1.6M Q3 '23: 6.8M Q4 '23: 5.4M Q1 '24: 7.8M Q2 '24: 8.9M Q3 '24: 6M Q4 '24: 5.6M Q1 '25: 8.6M Q2 '25: 7.1M Q3 '25: 8.2M Q4 '25: 8.8M Q1 '26: 6.5M Q2 '26: 6.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -40.2M Q4 '21: -25.9M Q1 '22: -46.7M Q2 '22: -27.9M Q3 '22: -15.4M Q4 '22: 10.4M Q1 '23: -31.7M Q2 '23: -2.8M Q3 '23: -13.3M Q4 '23: 14.3M Q1 '24: -18.6M Q2 '24: 15.8M Q3 '24: 17M Q4 '24: 30.1M Q1 '25: 1.3M Q2 '25: 44.2M Q3 '25: 44.4M Q4 '25: 45.7M Q1 '26: 32.6M Q2 '26: 52.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -40.3M Q4 '21: -26M Q1 '22: -46.8M Q2 '22: -27.9M Q3 '22: -15.4M Q4 '22: 10.3M Q1 '23: -32M Q2 '23: -3M Q3 '23: -13.4M Q4 '23: 14M Q1 '24: -18.6M Q2 '24: 15.7M Q3 '24: 16.9M Q4 '24: 30.1M Q1 '25: 1.3M Q2 '25: 44.1M Q3 '25: 44.4M Q4 '25: 45.6M Q1 '26: 32.5M Q2 '26: 52.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 112.6M Q3 '20: 122.4M Q1 '21: 127.4M Q2 '21: 128.2M Q3 '21: 128.4M Q1 '22: 141.7M Q2 '22: 141.7M Q3 '22: 141.9M Q1 '23: 142.6M Q2 '23: 142.8M Q3 '23: 142.8M Q1 '24: 144M Q2 '24: 144.1M Q3 '24: 145.7M Q1 '25: 143.2M Q2 '25: 137.5M Q3 '25: 136M Q1 '26: 137.6M Q2 '26: 133.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.60 -0.80 0.00 0.80 1.60 2.40 Q3 '21: -1.22 Q4 '21: -1.41 Q1 '22: -1.28 Q2 '22: -1.16 Q3 '22: -0.83 Q4 '22: -0.76 Q1 '23: -0.67 Q2 '23: -0.50 Q3 '23: -0.53 Q4 '23: -0.54 Q1 '24: -0.43 Q2 '24: -0.34 Q3 '24: -0.15 Q4 '24: 0.05 Q1 '25: 0.28 Q2 '25: 0.43 Q3 '25: 0.56 Q4 '25: 2.08 Q1 '26: 2.17 Q2 '26: 2.29 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.